🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Factbox: Dealmaking hits the rocks due to stormy markets

Published 07/01/2022, 10:38 AM
Updated 07/01/2022, 10:56 AM
© Reuters. A pedestrian passes by Novartis' Institutes for Biomedical Research in Cambridge, Massachusetts, U.S., January 2, 2020.  REUTERS/Brian Snyder/Files
KSS
-
FRG
-
JSTTY
-

(Reuters) - Efforts by companies to strike merger agreements with buyout firms are floundering in stormy markets, with private equity struggling to raise financing for bids big enough to satisfy shareholders and their boards.

These are firms that have withdrawn, postponed or changed plans of their M&A deals in recent days:

KOHL'S CORP

The U.S. department store chain called off its sale to Vitamin Shoppe-owner Franchise Group (NASDAQ:FRG) on July 1, blaming a downturn in market conditions.

Kohl's (NYSE:KSS) had entered exclusive talks with Franchise Group in June, valuing it at nearly $8 billion. Kohl's had rejected bids it received since January for undervaluing the company.

NOVARTIS

The Swiss drugmaker is considering a spin-off of its generic drug unit Sandoz rather than selling it to private equity firms, Bloomberg reported on June 30, citing unnamed sources amid a challenging macro environment.

JUST EAT (OTC:JSTTY) TAKEAWAY

Doubts on whether Europe's largest online food deliverer will successfully sell its U.S. Grubhub operation dragged shares to an all-time low at the end of June, although the company said it had not changed its strategy and funding was not in doubt.

WALGREENS BOOTS ALLIANCE

The British pharma company on June 28 scrapped plans to sell its UK pharmacy chain Boots, saying no third party was able to make an adequate offer for the company, which had been valued at as much as 8 billion pounds ($10 billion).

Several sources told Reuters that lender wariness had made raising the funds difficult for private equity bidders Apollo Global and TDR.

RECKITT BENCKISSER GROUP

© Reuters. A pedestrian passes by Novartis' Institutes for Biomedical Research in Cambridge, Massachusetts, U.S., January 2, 2020.  REUTERS/Brian Snyder/Files

The British consumer goods company might shelve a planned $7 billion sale of its infant nutrition unit due to a worsening financing market, including lack of available funding, Bloomberg News reported on June 29.

($1 = 0.8318 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.